Wednesday, September 26, 2007 11:57:48 AM
Significant Development in the Fight Against Advanced Rheumatoid Arthritis
IRVINE, CA, Sep 26, 2007 (MARKET WIRE via COMTEX) -- HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced today that the joint marketing program with Abbott Laboratories has commenced in Southern Ontario, Canada. The program is the first of its kind and offers Rheumatologists the option of prescribing "combination therapy" for patients with advanced rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
"The guidelines published by the American College of Rheumatology [ACR] for rheumatoid arthritis state that 'the ultimate goals in managing RA are to prevent or control joint damage, prevent loss of function, and decrease pain,'" said Dieter D. Doederlein, Vice President Corporate Development of HealthSonix. "To maintain joint function, the guidelines suggest that 'regular participation in dynamic and even aerobic conditioning exercise programs improves joint mobility, muscle strength, aerobic fitness and function, and psychological well being without increasing fatigue or joint symptoms.' That is why the combination therapy now offered by Abbott Laboratories and HealthSonix is a significant new development for both rheumatologists and their patients," said Doederlein.
Abbott's biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.
"This new program represents a significant development in the fight against arthritis because the ACR guidelines stress that the combination of medications and non-pharmacological therapies is the optimal way to treat the patients," said Doederlein.
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact
Recent ABT News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 11:37:36 AM
- Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range • PR Newswire (US) • 10/16/2024 11:30:00 AM
- Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping • PR Newswire (US) • 10/10/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:48:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:39:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:33:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:27:14 PM
- Abbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive' • PR Newswire (US) • 09/26/2024 06:00:00 PM
- Abbott Hosts Conference Call for Third-Quarter Earnings • PR Newswire (US) • 09/25/2024 01:00:00 PM
- Abbott Declares 403rd Consecutive Quarterly Dividend • PR Newswire (US) • 09/19/2024 04:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 09:24:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 10:20:12 PM
- Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. • PR Newswire (US) • 09/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:03:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:52:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/04/2024 08:04:41 PM
- Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression • PR Newswire (US) • 09/04/2024 01:00:00 PM
- Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores • PR Newswire (US) • 08/27/2024 01:00:00 PM
- AVEIR(MC) DR d'Abbott - Le premier système de stimulateur cardiaque double chambre sans sonde est maintenant offert au Canada • PR Newswire (Canada) • 08/15/2024 06:18:00 PM
- Abbott's AVEIR™ DR - World's First Dual Chamber Leadless Pacemaker System - Now Available in Canada • PR Newswire (Canada) • 08/15/2024 05:44:00 PM
- Québec élargit sa couverture publique du système flash de surveillance du glucose FreeStyle Libre 2 à un plus grand nombre d'adultes atteints de diabète • PR Newswire (Canada) • 08/08/2024 01:00:00 PM
- Quebec Expands Public Reimbursement of Abbott's FreeStyle Libre® 2 Flash Glucose Monitoring System to More Adults with Diabetes • PR Newswire (Canada) • 08/08/2024 01:00:00 PM
- Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices • PR Newswire (US) • 08/07/2024 12:00:00 PM
- Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices • PR Newswire (US) • 08/07/2024 12:00:00 PM
- Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs • PR Newswire (US) • 08/06/2024 01:00:00 PM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM